Arbutus Biopharma Corp. (NASDAQ:ABUS)‘s stock had its “sell” rating reiterated by equities research analysts at Chardan Capital in a report released on Sunday.
Other analysts have also recently issued reports about the company. Zacks Investment Research raised Arbutus Biopharma Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 18th. Leerink Swann cut Arbutus Biopharma Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 17th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective (up from $13.00) on shares of Arbutus Biopharma Corp. in a report on Friday, August 5th. Finally, William Blair reaffirmed an “outperform” rating on shares of Arbutus Biopharma Corp. in a report on Sunday, August 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $7.63.
Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) traded down 11.57% during midday trading on Friday, hitting $3.44. 860,300 shares of the company were exchanged. The company’s 50 day moving average price is $3.79 and its 200 day moving average price is $4.06. The firm’s market cap is $188.50 million. Arbutus Biopharma Corp. has a one year low of $2.72 and a one year high of $6.74.
Arbutus Biopharma Corp. (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.36. Arbutus Biopharma Corp. had a negative return on equity of 8.87% and a negative net margin of 1,017.01%. Equities analysts expect that Arbutus Biopharma Corp. will post ($3.35) EPS for the current year.
Institutional investors have recently bought and sold shares of the company. K2 Principal Fund L.P. boosted its position in Arbutus Biopharma Corp. by 113.6% in the second quarter. K2 Principal Fund L.P. now owns 63,550 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 33,796 shares during the period. AXA boosted its position in Arbutus Biopharma Corp. by 1.4% in the second quarter. AXA now owns 792,358 shares of the biopharmaceutical company’s stock worth $2,757,000 after buying an additional 11,062 shares during the period. Suffolk Capital Management LLC boosted its position in Arbutus Biopharma Corp. by 7.6% in the second quarter. Suffolk Capital Management LLC now owns 441,915 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 31,023 shares during the period. I.G. Investment Management LTD. acquired a new position in Arbutus Biopharma Corp. during the second quarter worth approximately $870,000. Finally, Bank of Montreal Can acquired a new position in Arbutus Biopharma Corp. during the second quarter worth approximately $2,822,000. 31.87% of the stock is owned by institutional investors.
Arbutus Biopharma Corp. Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.